C. Michael Gibson/cardiometabolichealth.org
Aug 29, 2026, 14:39
C. Michael Gibson: SINGLE-AF Trial Supports DOAC Use in Intermediate-Risk Atrial Fibrillation
C. Michael Gibson, President and CEO at Baim Institute for Clinical Research, Professor of Medicine at Harvard Medical School, Executive Board Member at EXCITE International, shared a post on LinkedIn:
“Single-AF trial: In patients with atrial fibrillation and intermediate stroke risk, DOAC therapy lowered the risk of net adverse clinical events (stroke, systemic embolism, major bleeding, or CV death) compared to no anticoagulation at 24 months.
Download slides here.”
Stay updated with Hemostasis Today.
-
Oct 17, 2026, 04:07Weihao Li: Global HEPATIC Registry Findings on Post-Transplant Arterial Thrombosis
-
Oct 17, 2026, 03:56Ghaith Abu-Zeinah: ASH Publishes 2026 Guidelines for Myelofibrosis Management in Blood Advances
-
Oct 17, 2026, 03:48Tristan Siokos: Why Vascular Occlusion Is More Than Just Clots – Breakdown of the 8 Pathways
-
Oct 17, 2026, 02:36Archil Jaliashvili: Oxygen Transport in Capillaries
-
Oct 17, 2026, 02:35Carly Newton: Understanding Access to Red Blood Cell Exchange for People Living With SCD
-
Oct 17, 2026, 02:34Raising Awareness of Blood Clots During and After Pregnancy – Thrombosis UK
-
Oct 17, 2026, 02:33Alaa Salamat: Our Research Accepted for Publication at ASH 2026
-
Oct 17, 2026, 02:32Mohammed Al Sharif: Discussing Factor XIII Testing and Its Clinical Significance
-
Oct 17, 2026, 02:31Joanna Popiolek-Kalisz: Talking about Novel Pharmacotherapy for Hypertension at CV Prevention and Intervention